Table 1.
Characteristics of the studies included in the meta-analysis
| First author | Year | Country | NAFLD criteria | PCOS criteria | PCOS (NAFLD)a | Control (NAFLD)# | NOSb |
|---|---|---|---|---|---|---|---|
| Cerda C | 2007 | Chile | Ultrasound | Rotterdam | 41 (17) | 31 (6) | 5 |
| Markou A | 2010 | Greece | Ultrasound | Rotterdam | 17 (0) | 17 (0) | 6 |
| Gutierrez-Grobe Y | 2010 | Mexico | Ultrasound | Not mentioned | 50 (31) | 147 (62) | 4 |
| Vassilatou E | 2010 | Greece | Ultrasound | AES | 57 (21) | 60 (12) | 5 |
| Hossain N | 2011 | USA | Histology | Rotterdam | 25 (11) | 25 (5) | 5 |
| Zueff LF | 2012 | Brazil | Ultrasound | Rotterdam | 45 (33) | 45 (21) | 5 |
| Karoli R | 2013 | India | Ultrasound | Rotterdam | 54 (36) | 55 (14) | 5 |
| Qu Z | 2013 | China | Ultrasound | Rotterdam | 602 (198) | 588 (109) | 5 |
| Kahal H | 2014 | UK | Ultrasound | Rotterdam | 19 (7) | 17 (0) | 6 |
| Bohdanowicz-Pawlak A | 2014 | Poland | Ultrasound | Rotterdam | 184 (106) | 125 (62) | 5 |
| Kuliczkowska Plaksej J | 2014 | Poland | Ultrasound | Rotterdam | 173 (92) | 125 (40) | 5 |
| Romanowski MD | 2015 | Brazil | Ultrasound | AES | 101 (24) | 30 (1) | 5 |
| Vassilatou E | 2015 | Greece | Ultrasound | Rotterdam | 40 (31) | 70 (40) | 6 |
| Macut D | 2016 | Greece Serbia | NAFLD-LFS | Rotterdam | 600 (304) | 125 (43) | 5 |
| Ayonrinde OT | 2016 | Australia | Ultrasound | NIH | 32 (12) | 167 (25) | 5 |
| Jie C | 2017 | China | Ultrasound | Rotterdam | 400 (225) | 100 (38) | 5 |
| Kim JJ | 2017 | Korea | Ultrasound | Rotterdam | 275 (15) | 892 (25) | 6 |
AES: Androgen Excess Society criteria
NAFLD-LFS: NAFLD liver fat score
aPCOS (NAFLD) means the total number of PCOS and the number of NAFLD in PCOS group
#control (NAFLD) means the total number of control and the number of NAFLD in control group
bThe quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) and the score ranged between 0 and 9